fbpx

molecules of the month

“PROTAC 6”

IAP-based selective RIPK2 degrader

prolonged PD w/ 0.15 mpk SC Q3D dosing

E3 binder switch and property-based opt.

Commun. Biol., Mar. 20, 2020

GlaxoSmithKline, Stevenage, UK / PMCC

“PROTAC 6”
1 min read

“PROTAC 6” (GlaxoSmithKline (GSK) IAP-based selective RIPK2 degrader with prolonged in vivo PD)


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: